Plasma Protein Binding Rate and Pharmacokinetics of Lekethromycin in Rats

• Main Authors: Pan Sun (Author), Hongzhi Xiao (Author), Jicheng Qiu (Author), Yuying Cao (Author), Jingyuan Kong (Author), Suxia Zhang (Author), Xingyuan Cao (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antibiotics11091241; 2079-6382
• Keywords: LKMS; plasma protein binding rate; pharmacokinetics; in vitro; in rats; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 11, Iss 9, p 1241 (2022)

Lekethromycin (LKMS), a novel macrolide lactone, is still unclear regarding its absorption. Thus, we conducted this study to investigate the characteristics of LKMS in rats. We chose the ultrafiltration method to measure the plasma protein binding rate of LKMS. As a result, LKMS was characterized by quick absorption, delayed elimination, and extensive distribution in rats following intramuscular (im) and subcutaneous (sc) administration. Moreover, LKMS has a high protein binding rate (78-91%) in rats at a concentration range of 10-800 ng/mL. LKMS bioavailability was found to be approximately 84-139% and 52-77% after im and sc administration, respectively; however, LKMS was found to have extremely poor bioavailability after oral administration (po) in rats. The pharmacokinetic parameters cannot be considered linearly correlated with the administered dose. Additionally, LKMS and its corresponding metabolites were shown to be metabolically stable in the liver microsomes of rats, dogs, pigs, and humans. Notably, only one phase I metabolite was identified during in vitro study, suggesting most of drug was not converted. Collectively, LKMS had quick absorption but poor absorption after oral administration, extensive tissue distribution, metabolic stability, and slow elimination in rats.